Thermidas: A Breakthrough in Non-Invasive Skin Temperature Measurement

By HEOR Staff Writer

August 21, 2023

FinCCHTA, the Finnish Coordinating Centre for Health Technology Assessment, has recommended the use of Thermidas, a non-invasive thermal imaging system, to support diagnostics and monitor treatment. The system, which includes imaging analysis and reporting software, is particularly useful for measuring skin surface temperature changes.

Thermidas has been shown to be effective in monitoring temperature differences, indicating changes in the circulatory index, subclinical infections, the severity of vascular disease, and specific complications of Charcot neuro-osteoarthropathy. It has also been found to be a reliable and reproducible method for measuring temperature across areas, compared to traditional point-like temperature measurements in healthy adults.

The system has been particularly beneficial in the monitoring of diabetic foot ulcers and rheumatoid arthritis. A study demonstrated that infrared thermal imaging was able to detect temperature differences in the feet of a group of patients at high risk due to diabetes. Another cross-sectional study showed that combined thermal and ultrasound imaging provides better information about the area under examination than either imaging method used alone in assessing arthritis in rheumatoid arthritis cases.

The Thermidas system is recommended for use until April 2026. The manufacturer has provided evidence of theoretical cost savings, particularly in the monitoring of diabetic podiatric conditions and inflammatory rheumatoid arthritis, as well as in support of diagnostics. The purchase price of the system includes deployment training, with post-acquisition product and maintenance support subject to a fee. 

Reference url

Recent Posts

Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program for Innovative Techno...

By HEOR Staff Writer

April 28, 2026

The European Medicines Agency (EMA) has launched a pilot programme to deliver breakthrough medical device access for high-risk technologies that address unmet medical needs. Starting 28 April 2026, the initiative offers enhanced scientific advice and priority access to expert panels for developer...
Medical Device Innovation South Africa: Breaking Down Systemic Barriers

By HEOR Staff Writer

April 27, 2026

Medical device innovation South Africa is hindered by deep structural obstacles that prevent locally developed technologies from reaching patients, despite the country’s considerable technical expertise. South Africa’s medical technology sector remains trapped in a cycle of heavy import dependenc...
Regulatory Divergence in PSMA Targeted Therapy: Implications for European Market Access
Novartis withdrew its European Medicines Agency (EMA) application to expand the indication for Pluvicto® (lutetium (177Lu) vipivotide tetraxetan). The company sought to include adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have not yet received chem...